Wealth Enhancement Advisory Services
SPRY icon

Wealth Enhancement Advisory Services’s ARS Pharmaceuticals SPRY Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60,294
Closed -$636K – 3151
2024
Q4 		$636K Buy
60,294
+2,670
+5% +$37.4K ﹤0.01% 1815
2024
Q3 		$836K Buy
57,624
+4,810
+9% +$57.2K ﹤0.01% 1495
2024
Q2 		$449K Sell
52,814
-10,994
-17% -$97.6K ﹤0.01% 1710
2024
Q1 		$652K Buy
63,808
+5
+0% +$37 ﹤0.01% 1441
2023
Q4 		$350K Buy
+63,803
New +$280K ﹤0.01% 1718

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wealth Enhancement Advisory Services's SPRY Position: Q1 2025 in Review

Wealth Enhancement Advisory Services sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 60,294 shares — an estimated $636K sold.

Wealth Enhancement Advisory Services first reported a position in SPRY in Q4 2023 and held it in 5 quarters. The position peaked at $836K in Q3 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Wealth Enhancement Advisory Services reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 60,294 ARS Pharmaceuticals shares in Q1 2025, an estimated $636K.
  • Wealth Enhancement Advisory Services first reported a position in ARS Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Wealth Enhancement Advisory Services's ARS Pharmaceuticals position peaked at $836K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2025, filed 16 Apr 2025.